Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | CDC25A | P30304 | 2/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5810776 | 0.83 | PARK7 (0.58) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL597656 | 0.79 | MEN1 (0.56) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL29525396 | 0.79 | MEN1 (0.56) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL10446630 | 0.79 | PTPN1 (0.52) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL4197326 | 0.79 | PTPN1 (0.52) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL9685830 | 0.79 | PTPN1 (0.52) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL3275939 | 0.79 | PTPN1 (0.52) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL7912021 | 0.79 | PTPN1 (0.52) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL14764741 | 0.78 | PTPN1 (0.54) | BACE1PTPN1MEN1KMT2ANSD2 | |
| SCHEMBL14764751 | 0.78 | PTPN1 (0.54) | BACE1PTPN1MEN1KMT2ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107226789-A | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared | 北京大学 | 2017-10-03 | — | — | CN | claimed |
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-20 | — | — | US | disclosed |
| CN-107226789-B | Dithiocarbamates compound, preparation method and purposes in the preparation of antitumor drugs | 北京大学 | 2019-11-08 | — | — | CN | disclosed |
| CN-107226789-A | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared | 北京大学 | 2017-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | NFE2L2, DUOX1, DUOX2 | BACE1 608/4885PTPN1 4633/4885MEN1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.